27032-63-9

Usage

Uses

Used in Pharmaceutical Industry:
(5-CHLORO-PYRIDIN-2-YL)-HYDRAZINE is used as a chemical intermediate for the synthesis of various pharmaceutical compounds, leveraging its unique chloro-pyridine functional group to create novel drug molecules with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, (5-CHLORO-PYRIDIN-2-YL)-HYDRAZINE is utilized as a precursor in the development of new agrochemicals, potentially enhancing crop protection and yield through targeted pest control and plant growth regulation.
Used in Materials Science:
(5-CHLORO-PYRIDIN-2-YL)-HYDRAZINE is employed as a component in the preparation of specialized polymers and materials, where its chemical structure contributes to the creation of materials with specific properties for various applications, such as high-performance plastics or advanced composites.
Used in Drug Discovery and Development:
(5-CHLORO-PYRIDIN-2-YL)-HYDRAZINE serves as a valuable building block in drug discovery and development, where its biological activity can be harnessed to design new pharmaceutical agents with improved efficacy and selectivity in treating diseases.

InChI:InChI=1S/C5H6ClN3/c6-4-1-2-5(9-7)8-3-4/h1-3H,7H2,(H,8,9)

Upstream product

• 16110-09-1 2,5 dichloropyridine 
• 40473-01-6 2-Bromo-5-chloro-pyridine 
• 1072-98-6 5-chloro-2-pyridylamine 

Downstream Products

• 104408-24-4 5-cyano-pyridin-2-ylhydrazine 
• 27032-65-1 cyclohexanone (5-chloropyridin-2-yl)hydrazone 
• 1072-98-6 5-chloro-2-pyridylamine 
• 1394062-37-3 3-chloro-6-methyl-6,7,8,9-tetrahydro-5H-pyrido-[3',4':4,5]pyrrolo[2,3-b]pyridine 
• 1159831-32-9 C₇H₄ClN₃O₂ 

Relevant academic research and scientific papers

Synthesis of 5-chloro-7-azaindoles by Fischer reaction

[Figure not available: see fulltext.] A simple and effective method on the basis of Fischer reaction in polyphosphoric acid is proposed for the synthesis of previously unknown heterocyclic structures that contain the 5-chloro-1H-pyrrolo[2,3-b]pyridine system. This method can be used for the synthesis of 3-substituted and 2,3-disubstituted 5-chloro-7-azaindoles with alkyl and aryl substituents.

HUMAN PLASMA KALLIKREIN INHIBITORS

Disclosed are compounds of formula (I), as described herein, and pharmaceutically acceptable salts thereof. The compounds are inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.

CYANINE DYES AND THEIR CONJUGATES

Compounds and methods are disclosed that are useful for noninvasive imaging in the near-infrared spectral range. The cyanine compounds of Formula (I), are presented: wherein Q is a portion of a polymethine bridge selected from the group consisting (Formula (X)). Also included are bioconjugates of the compounds of Formula (I), methods of labeling biomolecules with the compounds, and methods of imaging.

Design and synthesis of a new class of membrane-permeable triazaborolopyridinium fluorescent probes

A new class of fluorescent triazaborolopyridinium compounds was synthesized from hydrazones of 2-hydrazinylpyridine (HPY) and evaluated as potential dyes for live-cell imaging applications. The HPY dyes are small, their absorption/emission properties are

4-(PYRIDIN-3-YL)-2-(PYRIDIN-2-YL)-1,2-DIHYDRO-3H-PYRAZOL-3-ONE DERIVATIVES AS SPECIFIC HIF-PROLYL-4-HYDROXYLASE INHIBITORS FOR TREATING CARDIOVASCULAR AND HAEMATOLOGICAL DISEASES

The object of the invention is to provide new compounds which can be used for the treatment of diseases, in particular cardiovascular and haematological diseases. The present invention describes compounds which act as specific HIF-prolyl-4-hydroxylase inhibitors and which, because of this specific in vivo action mechanism, induce HIF target genes, such as erythropoietin, and the thus produced biological processes, such as erythropoiesis, after parenteral or oral administration. The present invention relates to compounds having the general formula (I), in which A stands for CH or N, R1 stands for a substituent selected from the group formed by (C1-C6)-alkyl, trifluoromethyl, halogen, cyano, nitro, hydroxy, (C1-C6)-alkoxy, amino, (C1-C6)-alkoxycarbonyl, hydroxycarbonyl and C(=O)-NH-R4; R2 stands for a substituent selected from the group formed by halogen, cyano, nitro, (C1-C6)-alkyl, trifluoromethyl, hydroxy, (C1-C6)-alkoxy, trifluoromethoxy, amino, hydroxycarbonyl and C(=O)-NH-R8; m equals 0, 1 or 2; n equals 0, 1, 2 or 3, it being possible for these meanings to be the same or different when R1 or R2 occurs multiple times; and R3 stands for hydrogen, (C1-C6)-alkyl or (C3-C7)-cycloalkyl. The invention also relates to the salts, solvates, and salt solvates of these compounds.

Condensed pyrazole derivatives, process for producing the same and use thereof

Novel pharmaceutical compositions for inhibiting Th2-selective immune response and pharmaceutical compositions for inhibiting cyclooxygenase comprising condensed pyrazole derivatives represented by the general formula (I): or salts thereof.

BICYCLIC TRIAZOLONE DERIVATIVES AND HERBICIDES CONTAINING THE SAME

The present invention provides a bicyclic triazolone derivative represented by the formula:J-Ar [wherein, J is and Ar is ], which has excellent selective weeding activity and weed killer containing the said bicyclic triazolone derivative.

2-(pyrazol-5-yl-oxymethyl)-1,2-benzisothiazol-3 (2H)-One 1, 1-dioxides and compositions and method of use thereof

2-(Pyrazol-5-yl-oxymethyl)-1,2-benzisothiazol-3(2H)-one 1,1-dioxides, pharmaceutical compositions containing them and methods for the treatment of degenerative diseases utilizing them.

Substituted 2-acylpyridine-α-(N)-hetarlyhydrazones and medicaments containing the same

Substituted 2-acylpyridine-α-(N)-hetarylhydrazones are described, which are suitable as active substances for the treatment of antimicrobial and in particular antimycobacterial diseases, as well as active substances for the treatment of malaria or malignant tumours. The compounds have a marked synergistic activity combined with inhibitors of folate synthase, dihydrofolic acid reductase, DNA-synthesis and RNA-synthesis.

Heterocyclic substituted-amino-pyrazolines

This invention relates to novel 3-amino-1-heteroaryl-2-pyrazolines and their C4 and C5 analogs, useful for meliorating the inflammation and/or the progressive joint deterioration characteristic of arthritic disease, preventing the onset of asthmatic symptoms and allergic diseases, or as analgesic, antibacterial or antifungal agents.